Literature DB >> 2007322

Stable isotope studies of nicotine kinetics and bioavailability.

N L Benowitz1, P Jacob, C Denaro, R Jenkins.   

Abstract

The stable isotope-labeled compound 3',3'-dideuteronicotine was used to investigate the disposition kinetics of nicotine in smokers, the systemic absorption of nicotine from cigarette smoke, and the bioavailability of nicotine ingested as oral capsules. Blood levels of labeled nicotine could be measured for 9 hours after a 30-minute intravenous infusion. Analysis of disposition kinetics in 10 healthy men revealed a multiexponential decline after the end of an infusion, with an elimination half-life averaging 203 minutes. This half-life was longer than that previously reported, indicating the presence of a shallow elimination phase. Plasma clearance averaged 14.6 ml/min/kg. The average intake of nicotine per cigarette was 2.29 mg. A cigarette smoke-monitoring system that directly measured particulate matter in smoke was evaluated in these subjects. Total particulate matter, number of puffs on the cigarette, total puff volume, and time of puffing correlated with the intake of nicotine from smoking. The oral bioavailability of nicotine averaged 44%. This bioavailability is higher than expected based on the systemic clearance of nicotine and suggests that there may be significant extrahepatic metabolism of nicotine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2007322     DOI: 10.1038/clpt.1991.28

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  23 in total

1.  Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes.

Authors:  P Jacob; L Yu; A T Shulgin; N L Benowitz
Journal:  Am J Public Health       Date:  1999-05       Impact factor: 9.308

2.  Nicotine reinforcement in never-smokers.

Authors:  Angela N Duke; Matthew W Johnson; Chad J Reissig; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2015-09-08       Impact factor: 4.530

3.  Population pharmacokinetics of nicotine and its metabolites I. Model development.

Authors:  Micha Levi; Delia A Dempsey; Neal L Benowitz; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-01-06       Impact factor: 2.745

Review 4.  Ulcerative colitis in smokers, non-smokers and ex-smokers.

Authors:  Guillermo Bastida; Belén Beltrán
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

5.  An oral formulation of nicotine for release and absorption in the colon: its development and pharmacokinetics.

Authors:  J T Green; B K Evans; J Rhodes; G A Thomas; C Ranshaw; C Feyerabend; M A Russell
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

6.  A clinical pharmacological study of subcutaneous nicotine.

Authors:  J Le Houezec; P Jacob; N L Benowitz
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Comparison of measured and FTC-predicted nicotine uptake in smokers.

Authors:  G D Byrd; J H Robinson; W S Caldwell; J D deBethizy
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

8.  Arrhythmia in the neonatal intensive care unit.

Authors:  Nadia Badrawi; Ranya A Hegazy; Edisa Tokovic; Wael Lotfy; Fadia Mahmoud; Hany Aly
Journal:  Pediatr Cardiol       Date:  2009-01-30       Impact factor: 1.655

9.  Adaptation of Predictive Models to PDA Hand-Held Devices.

Authors:  Edward J Lin; Thomas B Purcell; Rick A McPheeters
Journal:  West J Emerg Med       Date:  2008-01

10.  Attentional bias to smoking and other motivationally relevant cues is affected by nicotine exposure and dose expectancy.

Authors:  Jason D Robinson; Francesco Versace; Jeffery M Engelmann; Yong Cui; David G Gilbert; Andrew J Waters; Ellen R Gritz; Paul M Cinciripini
Journal:  J Psychopharmacol       Date:  2016-04-19       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.